XML 42 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Summary of Statutory Tax Rates Applicable to Income of Company and Subsidiaries

The Company is taxed according to U.S. federal and state tax laws and Israeli tax laws. The statutory tax rates applicable to the income of the Company and its subsidiaries for the periods presented are as follows:

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

89bio, Inc.

 

 

21

%

 

 

21

%

89Bio Ltd.

 

 

23

%

 

 

23

%

89bio Management, Inc.

 

 

21

%

 

 

21

%

UAB 89bio Lithuania

 

 

15

%

 

 

15

%

Summary of Income Tax (Expense) Benefit

The income tax (expense) benefit for the periods presented is comprised of (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Current:

 

 

 

 

 

 

Federal

 

 

 

 

State

 

 

(3

)

 

 

(2

)

Foreign

 

 

(16

)

 

 

(1

)

Total

 

 

(19

)

 

 

(3

)

Deferred:

 

 

 

 

 

 

Federal

 

 

 

 

150

 

State

 

 

 

 

Foreign

 

 

 

 

Total

 

 

 

 

150

 

Income tax (expense) benefit

 

 

(19

)

 

 

147

 

Summary of Components of Deferred Tax Assets Significant components of the Company’s deferred tax assets for the periods presented are as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2022

 

 

2021

 

U.S. net operating loss carryforwards

 

$

45,002

 

 

$

29,094

 

Research and development expenses

 

 

18,927

 

 

 

6,529

 

Israel net operating loss carryforwards

 

 

7,385

 

 

 

4,262

 

Stock-based compensation

 

 

4,328

 

 

 

1,969

 

Accrued expenses

 

 

317

 

 

 

220

 

Operating Lease Liability

 

 

98

 

 

 

 

Other

 

 

244

 

 

 

191

 

Gross deferred tax assets

 

 

76,301

 

 

 

42,265

 

Less: valuation allowance

 

 

(75,982

)

 

 

(42,046

)

 Total deferred tax assets

 

$

319

 

 

$

219

 

 

 

 

 

 

 

 

Operating lease right-of-use asset

 

 

(100

)

 

 

 

Total deferred tax liabilities

 

 

(100

)

 

 

 

 Net deferred tax assets

 

 

219

 

 

 

219

 

Summary of Loss from Operations Before Taxes on Income

The Company recorded a loss from operations, before income tax for the periods presented as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

United States

 

$

(101,938

)

 

$

(91,141

)

Lithuania

 

 

(7

)

 

 

10

 

Israel

 

 

(62

)

 

 

862

 

Net loss before income tax

 

$

(102,007

)

 

$

(90,269

)

Summary of Reconciliation of Income Tax (Expense) Benefit Statutory Tax Rate to Effective Tax Rate

The reconciliation of income tax (expense) benefit based on the statutory tax rate to the effective tax rate for the periods presented is as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Income tax benefit computed at statutory rates

 

$

21,429

 

 

$

18,757

 

Change in valuation allowance

 

 

(33,936

)

 

 

(20,111

)

Foreign rate differential

 

 

1

 

 

 

(19

)

State income taxes, net of federal benefit

 

 

5,824

 

 

 

 

State deferred tax true-up due to change in apportionment

 

 

6,517

 

 

 

 

Change in Israel effective tax rate due to the 2019 reorganization

 

 

 

 

 

(2

)

Research and development credits, net of uncertain tax position

 

 

2,130

 

 

 

1,331

 

Other

 

 

(1,984

)

 

 

191

 

Income tax (expense) benefit

 

$

(19

)

 

$

147

 

Summary of a Reconciliation of The Unrecognized Tax Benefits

A reconciliation of the unrecognized tax benefits for the year ended December 31, 2022 and 2021 is as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2022

 

 

2021

 

Balance beginning of year

 

 

851

 

 

 

329

 

Decrease related to prior year positions

 

 

(19

)

 

 

(35

)

Increase related to current year positions

 

 

752

 

 

 

557

 

 Balance end of year

 

 

1,584

 

 

 

851